SCHEMBL7234166

SCHEMBL7234166

Cc1ccc(-c2sc(NC(=N)N)nc2C)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 4/20 0.41
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 4/20 0.40
HPGD P15428 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 1/20 0.39
CLK1 P49759 1/20 0.39
CFTR P13569 1/20 0.39
PKM P14618 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL925362 0.81 MAPT (0.48) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL13074374 0.80 PIK3CD (0.52) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL10667475 0.80 PIK3CA (0.41) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL7232287 0.77 PIK3CG (0.42) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL10665462 0.77 MEN1 (0.43) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL7232027 0.74 TRPV4 (0.46) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7236363 0.74 CLEC4M (0.42) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL3608584 0.73 PIK3CG (0.51) PIK3CGMEN1KMT2AALDH1A1MAPT
SCHEMBL11080713 0.73 XIAP (0.48) PIK3CGMEN1KMT2AALDH1A1MAPT
Hydrochloric Acid SCHEMBL7142142 0.72 PIK3CD (0.50) PIK3CGMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed